fashion -WSS

fashion

author：fashion 2025-10-03 00:07:04 - browse：39338

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What would happen to your eyes if you looked at the solar eclipse?

WSS

Why we need to separate burnout from moral injury in health care

CDC concerned about possible undetected monkeypox spread in U.K.

Biden administration sends mixed signals on US soldier who crossed into North Korea

3 hurdles to bringing medical devices to the U.S. market

ER docs worry over extreme heat as a 'mass casualty event'

Cloning humans is technically possible. It's curious no one has tried

focus

fashion

focus

Dobbs anniversary: the lost opportunity of abortion as health care

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

In Memoriam: Notable people who died in 2023

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

23andMe had bad news about my health. I wish a person had delivered it

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

ChatGPT in medicine: STAT answers readers' burning questions

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Medical leaders decry Supreme Court decision on affirmative action

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

focus

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

The strategy behind pharma's lawsuits over drug pricing reform

ER docs worry over extreme heat as a 'mass casualty event'

A strong 6.5

House passes resolution saying Israel isn't a 'racist or apartheid state'

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

hotspot

hotspot

explore